PHM Stock Overview
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Pharma Mar, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €28.68 |
52 Week High | €47.10 |
52 Week Low | €28.30 |
Beta | -0.018 |
1 Month Change | -15.80% |
3 Month Change | -34.43% |
1 Year Change | -37.41% |
3 Year Change | -71.94% |
5 Year Change | 62.36% |
Change since IPO | -39.49% |
Recent News & Updates
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Recent updates
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Shareholder Returns
PHM | ES Biotechs | ES Market | |
---|---|---|---|
7D | -6.3% | -8.7% | 2.8% |
1Y | -37.4% | -17.5% | 16.7% |
Return vs Industry: PHM underperformed the Spanish Biotechs industry which returned -17.5% over the past year.
Return vs Market: PHM underperformed the Spanish Market which returned 16.7% over the past year.
Price Volatility
PHM volatility | |
---|---|
PHM Average Weekly Movement | 4.2% |
Biotechs Industry Average Movement | 7.6% |
Market Average Movement | 3.2% |
10% most volatile stocks in ES Market | 6.7% |
10% least volatile stocks in ES Market | 0.7% |
Stable Share Price: PHM's share price has been volatile over the past 3 months.
Volatility Over Time: PHM's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | 509 | Jose Fernandez Sousa-Faro | https://www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer.
Pharma Mar, S.A. Fundamentals Summary
PHM fundamental statistics | |
---|---|
Market cap | €505.91m |
Earnings (TTM) | €1.14m |
Revenue (TTM) | €158.15m |
444.9x
P/E Ratio3.2x
P/S RatioIs PHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHM income statement (TTM) | |
---|---|
Revenue | €158.15m |
Cost of Revenue | €9.61m |
Gross Profit | €148.54m |
Other Expenses | €147.40m |
Earnings | €1.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.064 |
Gross Margin | 93.92% |
Net Profit Margin | 0.72% |
Debt/Equity Ratio | 20.6% |
How did PHM perform over the long term?
See historical performance and comparison